ESTA vs JNJ
ESTA: Establishment Labs is a medical technology company advancing women's health through its next-generation Motiva breast implant technology and aesthetic surgical solutions. JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges.
Side-by-side fundamentals
| Metric | ESTA | JNJ | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $72.67 | $270.24 | |
| Market cap as of 2026-08-24 | $2.2B | $651.3B | |
| P/E as of 2026-08-24 | n/a | 29.93 | |
| PEG as of 2026-08-24 | n/a | 3.39 | |
| Net margin as of 2026-08-24 | -19.1% | +21.5% | JNJ higher |
| Gross margin as of 2026-08-24 | +70.1% | +68.0% | ESTA higher |
| Operating margin as of 2026-08-24 | -12.4% | +25.7% | JNJ higher |
| ROE as of 2026-08-24 | -225.9% | +25.7% | JNJ higher |
| ROA as of 2026-08-24 | -12.7% | +10.6% | JNJ higher |
| Debt / equity as of 2026-08-24 | 17.58 | 0.58 | JNJ lower |
| Revenue growth (YoY) as of 2026-08-24 | +34.9% | +8.1% | ESTA higher |
| Revenue CAGR (3y) SEC XBRL | +9.3% | +6.2% | ESTA higher |
| Dividend yield as of 2026-08-24 | n/a | +3.1% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-24 | 1.07 | 0.20 | |
| 1-year return as of 2026-08-21 close | +81.7% | +51.0% | ESTA higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.